Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharma (NASDAQ: VRTX ) stock is dropping on Friday following the release of results from a Phase 2 clinical trial. Source: Shutterstock That trial was testing the effectiveness of VX-864 . This is a po...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ChemoCentryx (NASDAQ: CCXI ) stock is on the rise Friday as investors boost it higher in anticipation of one of its treatments getting approval from the U.S. Food and Drug Administration (FDA). Source: Shutterstoc...
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor Corporation (MX) +24%...
ChemoCentryx (CCXI) announces presentations highlighting outcomes of its Phase III ADVOCATE trial and Phase II ACCOLADE and LUMINA-1 trials as part of the annual meeting of the ERA-EDTA, held virtually June 5-8, 2021. The data rom Phase III ADVOCATE trial showed that treatment with avacopan i...
-- Abstract on ‘The Effect of Avacopan, a Complement C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis with Renal Disease’ honored on “Ten Best” list by the Paper Selection Committee of ERA-EDTA -- -- Abstract on t...
Radnor, Pennsylvania--(Newsfile Corp. - June 7, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of those who purchased or acquired C...
Shares of ChemoCentryx (NASDAQ: CCXI) suffered an ugly 79% plunge in May, according to data provided by S&P Global Market Intelligence , after a Food and Drug Administration advisory committee offered up a split opinion on the efficacy of avacopan, the biotech's treatment fo...
RADNOR, PA / ACCESSWIRE / June 1, 2021 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of ChemoCentryx, Inc. (NASDAQ:CCXI) ("ChemoCentryx") that a securities fraud class action lawsuit has been filed against on behalf of those who purchased or acquired ChemoCentryx...
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”) (NASDAQ: CCXI) in the United States District Court for the Northern District...
Alfi (ALF) +35%.SemiLEDs Corporation (LEDS) +19%.Protagenic Therapeutics (PTIX) +18%.Party City Holdco (PRTY) +12% on Q1 results.BioNTech SE (BNTX) +9% on Q1 results.Aptorum Group Limited (APM) +8%.VYNE Therapeutics (VYNE) +8%.Inovio Pharmaceuticals (INO) +8% on positive data f...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...